SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sun Pharma Advanced Research Company informs about press release

30 Apr 2026 Evaluate
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Sun Pharma Advanced Research Company has informed that it enclosed the Press Release titled ‘SPARC Announces Sale of Priority Review Voucher for US $ 195 million (One Hundred and Ninety-Five Million Dollars)’, which the company shall be releasing after sending this letter. The disclosure required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI LODR’) read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 for the Sale of Priority Review Voucher is provided in Annexure A.

The above information is a part of company’s filings submitted to BSE.

Sun Pharma Adv. Res Share Price

142.85 -5.50 (-3.71%)
30-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Syngene Internation. 467.90
Indegene 499.55
CMS Info Systems 290.85
JITF Infralogistics 300.00
Sagility 41.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×